Variation in seizure risk increases from antiseizure medication withdrawal among patients with well‐controlled epilepsy: A pooled analysis

Author:

Terman Samuel W.1ORCID,Slinger Geertruida2ORCID,Koek Adriana13,Skvarce Jeremy4,Springer Mellanie V.1,Ziobro Julie M.5,Burke James F.6,Otte Willem M.2ORCID,Thijs Roland D.789,Lossius Morten I.1011,Marson Anthony G.12,Bonnett Laura J.13,Braun Kees P. J.2

Affiliation:

1. Department of Neurology University of Michigan Ann Arbor Michigan USA

2. Department of Child Neurology, UMC Utrecht Brain Center, Wilhelmina Children's Hospital University Medical Center Utrecht and Utrecht University Utrecht The Netherlands

3. Department of Neurology University of California San Francisco San Fransisco California USA

4. University of Michigan Medical School Ann Arbor Michigan USA

5. Department of Pediatrics University of Michigan Ann Arbor Michigan USA

6. Department of Neurology The Ohio State University Columbus Ohio USA

7. Stichting Epilepsie Instellingen Nederland (SEIN) Heemstede The Netherlands

8. Department of Neurology Leiden University Medical Centre (LUMC) Leiden The Netherlands

9. Queen Square Institute of Neurology University College London London UK

10. Oslo University Hospital National Center for Epilepsy Oslo Norway

11. Institute of Clinical Medicine, University of Oslo Oslo Norway

12. Department of Pharmacology and Therapeutics University of Liverpool Liverpool UK

13. Department of Health Data Science University of Liverpool Liverpool UK

Abstract

AbstractObjectiveGuidelines suggest considering antiseizure medication (ASM) discontinuation in seizure‐free patients with epilepsy. Past work has poorly explored how discontinuation effects vary between patients. We evaluated (1) what factors modify the influence of discontinuation on seizure risk; and (2) the range of seizure risk increase due to discontinuation across low‐ versus high‐risk patients.MethodsWe pooled three datasets including seizure‐free patients who did and did not discontinue ASMs. We conducted time‐to‐first‐seizure analyses. First, we evaluated what individual patient factors modified the relative effect of ASM discontinuation on seizure risk via interaction terms. Then, we assessed the distribution of 2‐year risk increase as predicted by our adjusted logistic regressions.ResultsWe included 1626 patients, of whom 678 (42%) planned to discontinue all ASMs. The mean predicted 2‐year seizure risk was 43% [95% confidence interval (CI) 39%–46%] for discontinuation versus 21% (95% CI 19%–24%) for continuation. The mean 2‐year absolute seizure risk increase was 21% (95% CI 18%–26%). No individual interaction term was significant after correcting for multiple comparisons. The median [interquartile range (IQR)] risk increase across patients was 19% (IQR 14%–24%; range 7%–37%). Results were unchanged when restricting analyses to only the two RCTs.SignificanceNo single patient factor significantly modified the influence of discontinuation on seizure risk, although we captured how absolute risk increases change for patients that are at low versus high risk. Patients should likely continue ASMs if even a 7% 2‐year increase in the chance of any more seizures would be too much and should likely discontinue ASMs if even a 37% risk increase would be too little. In between these extremes, individualized risk calculation and a careful understanding of patient preferences are critical. Future work will further develop a two‐armed individualized seizure risk calculator and contextualize seizure risk thresholds below which to consider discontinuation.Plain Language SummaryUnderstanding how much antiseizure medications (ASMs) decrease seizure risk is an important part of determining which patients with epilepsy should be treated, especially for patients who have not had a seizure in a while. We found that there was a wide range in the amount that ASM discontinuation increases seizure risk—between 7% and 37%. We found that no single patient factor modified that amount. Understanding what a patient's seizure risk might be if they discontinued versus continued ASM treatment is critical to making informed decisions about whether the benefit of treatment outweighs the downsides.

Funder

Michigan Institute for Clinical and Health Research

National Institute on Aging

National Institutes of Health

NIH Clinical Center

Universitair Medisch Centrum Utrecht

Publisher

Wiley

Subject

Neurology (clinical),Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3